Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2006

View Archived Issues

Studies assess pharmacodynamics, mechanism of action of ceftobiprole

Studies assess cancer prevention with selenium compounds

Schering-Plough selects compound for metabolic disease from collaboration

Reata licenses tricyclic bis-enones antiinflammatory compounds

Cytokinetics studies SB-743921 for NHL

PhG-alpha1 delays establishment and growth of colorectal cancer tumors in mice

Positive results for CRx-170 in proof-of-concept asthma study

Schering AG Boards recommend acceptance of Bayer offer

Isis licenses HIV inhibitor ISIS-5320 to ImQuest

Technosphere Insulin System improves HbA1c in phase II study

Schering-Plough updates status of phase II study of SCH-503034

Chiron shareholders approve acquisition by Novartis

Nonapprovable letter for Hexvix NDA

New compound class from Trubion Pharmaceuticals for B-cell chronic lymphocytic leukemias

PRX-08066 reduces systolic pulmonary blood pressure in study

Antitumor efficacy of new CD40 agonist antibody

Vesicare approved as first drug for overactive bladder in Japan

Funguard approved for use in children in Japan

Chugai seeks Japanese approval for Avastin in colorectal cancer

Japanese approval for Cetrotide for premature ovulation

New treatments for cancer covered in recent patents

Zometa receives new approval in Japan

AmBisome receives Japanese approval

Feron approved in Japan for compensatory cirrhosis C

Japanese approval for Nu-Lotan in diabetic nephropathy

HIV integrase inhibitors claimed in recent Pfizer patent

Novel cathepsin K inhibitor as a potential antiresorptive agent to treat osteoporosis

Synthesis and in vitro evaluation of new potent GAR Tfase inhibitor

Multinational phase III study shows positive results for panitumumab in metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...